Literature DB >> 23509221

Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects.

Katarína Sebeková, Zora Krivošíková, Martin Gajdoš.   

Abstract

BACKGROUND: Interaction of advanced glycation end products (AGEs) with their specific cell-surface receptor for AGEs (RAGE) induces production of reactive oxygen species, pro-diabetic, pro-inflammatory, and pro-atherogenic responses. The metabolic syndrome (Metsy) imposes a high risk of development of cardiovascular disease and unequivocally predisposes the non-diabetics to type 2 diabetes mellitus. The aim of the study was to investigate the association between circulating soluble RAGE (sRAGE), Nε-(carboxymethyl)lysine (CML) or AGE-associated fluorescence of plasma (AGE-Fl) with the number of manifested Metsy risk factors in young-to-middle-aged medication-free non-diabetic subjects.
METHODS: Metsy was classified according to NCEP/ATP III criteria; plasma sRAGE and total CML were determined by ELISA methods and AGE-Fl fluorimetrically.
RESULTS: From among 437 participants aged 33±11 years, 58% were females. In total 174 subjects were Metsy risk factors-free, 142 presented one, 59 presented two risk factors, and 62 suffered from Metsy. Plasma sRAGE and CML/albumin levels decreased with increasing number of Metsy risk factors (p<0.01, both), while AGE-Fl/albumin levels remained similar. Multivariate analysis selected waist circumference as a main determinant of plasma sRAGE as well as CML/albumin levels.
CONCLUSIONS: In young-to-middle-aged non-diabetic medication-free subjects plasma total CML/albumin and sRAGE levels decrease prior to the manifestation of Metsy. With regards to RAGE-mediated CML trapping into adipose tissue inducing dysregulation of pro-inflammatory cytokines, adipokines, and the development of obesity-related insulin resistance, and the potential involvement of sRAGE in feedback regulation of the toxic effects of AGE/RAGE-mediated signaling, this early decline might be of clinical impact in development of type 2 diabetes and its complications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23509221     DOI: 10.1515/cclm-2012-0879

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  17 in total

1.  Circulating Advanced Glycation Endproducts and Long-Term Risk of Cardiovascular Mortality in Kidney Transplant Recipients.

Authors:  Camilo G Sotomayor; António W Gomes-Neto; Marco van Londen; Rijk O B Gans; Ilja M Nolte; Stefan P Berger; Gerjan J Navis; Ramón Rodrigo; Henri G D Leuvenink; Casper G Schalkwijk; Stephan J L Bakker
Journal:  Clin J Am Soc Nephrol       Date:  2019-09-17       Impact factor: 8.237

2.  Advanced Glycation End Products: Building on the Concept of the "Common Soil" in Metabolic Disease.

Authors:  Henry H Ruiz; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

3.  Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study.

Authors:  Radana Gurecká; Ivana Koborová; Melinda Csongová; Jozef Šebek; Katarína Šebeková
Journal:  Glycoconj J       Date:  2016-06-14       Impact factor: 2.916

4.  Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer.

Authors:  Zhigang Duan; Guoqing Chen; Liang Chen; Rachael Stolzenberg-Solomon; Stephanie J Weinstein; Satu Mannisto; Donna L White; Demetrius Albanes; Li Jiao
Journal:  Int J Mol Epidemiol Genet       Date:  2014-10-22

5.  Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity?

Authors:  Jaime Uribarri; Weijing Cai; Mark Woodward; Elizabeth Tripp; Laurie Goldberg; Renata Pyzik; Kalle Yee; Laurie Tansman; Xue Chen; Venkatesh Mani; Zahi A Fayad; Helen Vlassara
Journal:  J Clin Endocrinol Metab       Date:  2015-02-19       Impact factor: 5.958

6.  A Comparative Study on Skin and Plasma Advanced Glycation End Products and Their Associations with Arterial Stiffness.

Authors:  Chang-Yuan Liu; Qi-Fang Huang; Yi-Bang Cheng; Qian-Hui Guo; Qi Chen; Yan Li; Ji-Guang Wang
Journal:  Pulse (Basel)       Date:  2016-12-21

7.  Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study.

Authors:  Barry I Hudson; Chuanhui Dong; Hannah Gardener; Mitchell S V Elkind; Clinton B Wright; Ron Goldberg; Ralph L Sacco; Tatjana Rundek
Journal:  Metabolism       Date:  2014-06-04       Impact factor: 8.694

Review 8.  Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.

Authors:  Magdalena Pertynska-Marczewska; Zaher Merhi
Journal:  Reprod Sci       Date:  2014-09-16       Impact factor: 3.060

9.  Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study.

Authors:  Haruki Momma; Kaijun Niu; Yoritoshi Kobayashi; Cong Huang; Masahiko Chujo; Atsushi Otomo; Hiroko Tadaura; Toshio Miyata; Ryoichi Nagatomi
Journal:  Diabetol Metab Syndr       Date:  2014-03-06       Impact factor: 3.320

10.  Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents.

Authors:  Chih-Tsueng He; Chien-Hsing Lee; Chang-Hsun Hsieh; Fone-Ching Hsiao; Philip Kuo; Nain-Feng Chu; Yi-Jen Hung
Journal:  Int J Endocrinol       Date:  2014-01-20       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.